Related references
Note: Only part of the references are listed.Final Analysis of the Efficacy and Safety of Omacetaxine Mepesuccinate in Patients With Chronic- or Accelerated-Phase Chronic Myeloid Leukemia: Results With 24 Months of Follow-Up
Jorge E. Cortes et al.
CANCER (2015)
Omacetaxine mepesuccinate in patients with advanced chronic myeloid leukemia with resistance or intolerance to tyrosine kinase inhibitors
H. Jean Khoury et al.
LEUKEMIA & LYMPHOMA (2015)
Cancer Statistics, 2014
Rebecca Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2014)
Drug-drug interactions with tyrosine-kinase inhibitors: a clinical perspective
Roelof W. F. van Leeuwen et al.
LANCET ONCOLOGY (2014)
Updated Product Label Allows Home Administration of Omacetaxine Mepesuccinate
Ann Q. Shen et al.
ONCOLOGIST (2014)
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
Yaoyu Chen et al.
ONCOTARGETS AND THERAPY (2014)
Phase 2 study of subcutaneous omacetaxine mepesuccinate for chronic-phase chronic myeloid leukemia patients resistant to or intolerant of tyrosine kinase inhibitors
J. Cortes et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Trends in all-cause mortality among patients with chronic myeloid leukemia
Andrew M. Brunner et al.
CANCER (2013)
Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors
John Nemunaitis et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2013)
A Phase 2 Trial of Ponatinib in Philadelphia Chromosome-Positive Leukemias
J. E. Cortes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Phase 2 study of subcutaneous omacetaxine mepesuccinate after TKI failure in patients with chronic-phase CML with T315I mutation
Jorge Cortes et al.
BLOOD (2012)
Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure
H. Jean Khoury et al.
BLOOD (2012)
Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience
Hagop Kantarjian et al.
BLOOD (2012)
Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis
H. J. Khoury et al.
BONE MARROW TRANSPLANTATION (2012)
Estimations of the increasing prevalence and plateau prevalence of chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy
Xuelin Huang et al.
CANCER (2012)
Tyrosine kinase inhibitors and drug interactions: a review with practical recommendations
Bella Pajares et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2012)
Predictive factors for outcome and response in patients treated with second-generation tyrosine kinase inhibitors for chronic myeloid leukemia in chronic phase after imatinib failure
Elias Jabbour et al.
BLOOD (2011)
Drug interactions with the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib
Amina Haouala et al.
BLOOD (2011)
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet
Simona Soverini et al.
BLOOD (2011)
Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
Jorge E. Cortes et al.
BLOOD (2011)
Success Story of Targeted Therapy in Chronic Myeloid Leukemia: A Population-Based Study of Patients Diagnosed in Sweden From 1973 to 2008
Magnus Bjorkholm et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells
E. K. Allan et al.
LEUKEMIA (2011)
Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
Dragana Milojkovic et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2010)
Nilotinib versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia
Giuseppe Saglio et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet
Michele Baccarani et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A. Hochhaus et al.
LEUKEMIA (2009)
Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and β-catenin
Junya Kuroda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2008)
Homoharringtonine induces apoptosis and growth arrest in human myeloma cells
Yin-Jun Lou et al.
LEUKEMIA & LYMPHOMA (2007)
Share Paper
